VRP is a calcium channel blocker that was intended for use in the treatment of hypertension and angina for decades, and it is a P-gp inhibitor that reverses MDR caused by ABCB1 in vitro (7, 53). This evidence concerns the gene ABCB1 and angina pectoris.